KURA
Kura Oncology, Inc.
NASDAQ · USHealthcareBiotechnology
$10.68-1.66%
Price as of Jul 20, 2026
KURA financials
Kura Oncology, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $67.5M | $53.9M | $0.00 | $0.00 |
| Cost of revenue | $57.0K | $0.00 | $849.0K | $0.00 |
| Gross profit | $67.4M | $53.9M | -$849.0K | $0.00 |
| Operating expenses | $371.1M | $247.1M | $165.0M | $139.9M |
| Operating income | -$303.6M | -$193.2M | -$165.8M | -$139.9M |
| Net income | -$278.7M | -$174.0M | -$152.6M | -$135.8M |
| EBITDA | -$275.8M | -$169.5M | -$150.2M | -$134.9M |
| Basic EPS | $-3.18 | $-2.02 | $-2.08 | $-2.03 |
| Diluted EPS | $-3.18 | $-2.02 | $-2.08 | $-2.03 |
| Balance sheet | ||||
| Cash & equivalents | $149.1M | $224.5M | $37.3M | $51.8M |
| Total assets | $738.4M | $760.2M | $448.9M | $456.3M |
| Total liabilities | $564.2M | $346.5M | $51.7M | $36.0M |
| Stockholders’ equity | $174.1M | $413.6M | $397.3M | $420.3M |
| Total debt | $20.5M | $16.6M | $17.2M | $14.0M |
| Net debt | -$128.6M | -$207.9M | -$20.1M | -$37.8M |
| Cash flow | ||||
| Operating cash flow | -$64.1M | $134.3M | -$124.8M | -$110.1M |
| Capital expenditure | -$6.6M | -$472.0K | -$168.0K | -$626.0K |
| Free cash flow | -$70.7M | $133.8M | -$125.0M | -$110.7M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |